Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. It offers nucleic acid and real-time PCR kits, as well as consumables. The company was founded in 2005 and is based in Shanghai, China.
Shanghai ZJ Bio-Tech Co. Ltd. A (688317) - Total Assets
Latest total assets as of September 2025: CN¥3.72 Billion CNY
Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) holds total assets worth CN¥3.72 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai ZJ Bio-Tech Co. Ltd. A - Total Assets Trend (2013–2024)
This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai ZJ Bio-Tech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai ZJ Bio-Tech Co. Ltd. A's total assets of CN¥3.72 Billion consist of 77.5% current assets and 22.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 73.4% |
| Accounts Receivable | CN¥59.90 Million | 1.6% |
| Inventory | CN¥57.37 Million | 1.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥7.80 Million | 0.2% |
| Goodwill | CN¥5.40 Million | 0.1% |
Asset Composition Trend (2013–2024)
This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai ZJ Bio-Tech Co. Ltd. A's current assets represent 77.5% of total assets in 2024, an increase from 48.5% in 2013.
- Cash Position: Cash and equivalents constituted 73.4% of total assets in 2024, up from 14.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai ZJ Bio-Tech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Shanghai ZJ Bio-Tech Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai ZJ Bio-Tech Co. Ltd. A generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shanghai ZJ Bio-Tech Co. Ltd. A is currently not profitable relative to its asset base.
Shanghai ZJ Bio-Tech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.06 | 19.89 | 4.11 |
| Quick Ratio | 22.65 | 18.50 | 3.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.81 Billion | CN¥ 2.92 Billion | CN¥ 1.20 Billion |
Shanghai ZJ Bio-Tech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai ZJ Bio-Tech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.19 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -7.0% |
| Total Assets | CN¥3.79 Billion |
| Market Capitalization | $274.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai ZJ Bio-Tech Co. Ltd. A's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai ZJ Bio-Tech Co. Ltd. A's assets decreased by 7.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2024)
The table below shows the annual total assets of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.79 Billion | -6.98% |
| 2023-12-31 | CN¥4.07 Billion | -14.12% |
| 2022-12-31 | CN¥4.74 Billion | +11.50% |
| 2021-12-31 | CN¥4.25 Billion | +126.36% |
| 2020-12-31 | CN¥1.88 Billion | +192.80% |
| 2019-12-31 | CN¥641.93 Million | +10.75% |
| 2018-12-31 | CN¥579.64 Million | +12.31% |
| 2017-12-31 | CN¥516.12 Million | -1.98% |
| 2016-12-31 | CN¥526.57 Million | +33.55% |
| 2015-12-31 | CN¥394.29 Million | +97.51% |
| 2014-12-31 | CN¥199.63 Million | +17.58% |
| 2013-12-31 | CN¥169.78 Million | -- |